The Annals of pharmacotherapy
-
To review the clinical trial data, pharmacology, pharmacokinetics, and adverse effects of brentuximab vedotin. ⋯ Phase 1 and 2 clinical trial data indicate that brentuximab vedotin is efficacious and safe in patients with relapsed and refractory CD30-positive lymphomas. This agent is being investigated in combination with chemotherapy to further elucidate its role in lymphoma therapy.